Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | MLYCD | O95822 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.32 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12442980 | 0.79 | KDM4E (0.34) | ALDH1A1 | |
| SCHEMBL23866608 | 0.78 | PKM (0.42) | CYP2D6CYP2C19MLYCDCYP2C9KMT2A | |
| SCHEMBL17768026 | 0.77 | CYP2D6 (0.44) | CYP2D6CYP2C19 | |
| SCHEMBL11652880 | 0.76 | ANPEP (0.37) | ANPEPDNPEPCYP2D6CYP2C19CYP2C9 | |
| SCHEMBL20102958 | 0.74 | ANPEP (0.40) | ANPEPDNPEPCYP2D6CYP2C19CYP2C9 | |
| Oxalic Acid SCHEMBL14842505 | 0.73 | CYP2D6 (0.41) | CYP2D6CYP2C19 | |
| SCHEMBL24333748 | 0.73 | CYP2D6 (0.33) | CYP2D6CYP2C19MLYCDCYP2C9KMT2A | |
| SCHEMBL27678507 | 0.72 | ALDH1A1 (0.39) | ANPEPDNPEPCYP2D6CYP2C19CYP2C9 | |
| SCHEMBL24333747 | 0.72 | ERCC1 (0.33) | ERCC1ERCC4 | |
| SCHEMBL19699643 | 0.72 | MEN1 (0.44) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | ANPEP 4096/4885DNPEP 3039/4885CYP2D6 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.